Kornimate/medical-research-clean huggingface dataset:
the efficacy and safety of using the novel tyto device

Conditions: Pharyngitis; Respiratory Diseases; Cardiac Diseases; Ear Infection

Summary: to investigate the efficacy and safety of using the novel tyto device for remote physical examination by co-investigators as compared to a standard medical physical examination by physicians.

a single center, prospective, qualitative study. patients referred to the emergency department will be triaged according to the canadian triage \& acuity scale (ctas). patients presenting with complaints suitable for examination with the tyto device (ear/throat/respiratory/cardiac complaints) and meeting the inclusion criteria will be informed and asked for consent. patients participating in the study will be referred to a room dedicated for the purpose. a minimum of a hundred volunteer patients will be selected and enrolled for a preliminary pilot study. final study design and its extent will be determined accordingly. physical examinations using the tyto device will be performed by the co-investigators, and sent online to the principle investigator for remote analysis. the emergency department physician will examine the patient using conventional examination instruments (i.e. stethoscope, otoscope). the data collected will be recorded on predetermined case report form (crf), timed, stored and analyzed by the principle and co-investigators. the findings of the co-investigators' examination will be compared to the conventional examination instruments used by the emergency department physician. results will be checked and compared categorically (0-inconclusive; 1-normal; 2-pathological findings)

Eligibility criteria:
inclusion criteria: * patients who present to the emergency department and are categorized between 2-5 on the canadian triage \& acuity scale (ctas) scoring scale. exclusion criteria: * ctas 1. * pregnant adolescent. * multi-drug resistant carriers. * intellectual disability disorders. * unsigned informed consent. * patients with ctas score of 2-3, will be first addressed by a physician to ascertain their eligibility to be enrolled to the study.
clinical evaluation of polyherbal coded formulation obesecure for leptin regulation and obesity management

Conditions: Leptin Deficiency; Obesity

Summary: the study was designed to explore an alternative approach to reduce weight in human beings using a polyherbal formulation. a polyherbal formulation named as obesecure was developed after screening of local medicinal flora. the formulation was further improved after pilot studies and phase-i clinical trials.

obesity is a common disease of developing countries including pakistan. obesity is a risk factor for many diseases which can be life-threatening or making the person unable to perform daily routine work. obesity is considered a risk factor for different diseases like cardiovascular diseases, hormonal imbalance, infections, malignancies and chest problems. the leptin hormone has appetite suppressing and energy dissipation activity in the body. a screening study on animals was carried out to find out the leptin enhancing medicinal plants from locally available plants in pakistan. this study was aimed to see the combined effects of the leptogenic drug obesecure on weight management. patients of age20 to 50 years with bmi more than 25, not taking any anti-obesity drugs one-month prior to start of study were enrolled. the participants were randomly allocated to receive either obesecure or placebo twice a day for three months in shifa-ul-mulk hospital, priem health care clinic (pakistan) and ria eastern medicine clinic (pakistan). an acute toxicity study showed no adverse effect of taking obesecure prior to clinical trials.

Eligibility criteria:
inclusion criteria: 1. patients of age20 to 50 years with bmi more than 25 2. only those participants were included who were willing 3. patients of any marital status were included 4. only those participants were included who did not take any antiobesity drug one-month prior to start of study exclusion criteria: 1. taking an anti-obesity drug in the previous month 2. pregnant 3. allergic to laxative drugs 4. recurrent weight gain history after antiobesity treatment 5. liver disease 6. taking hormonal therapy, menopausal women 7. diabetes mellitus 8. cardiac problem and hypertension
pharmacokinetics and tolerability of meloxicam injected intramuscularly vs. tablet in healthy subjects

Conditions: Healthy

Summary: study to investigate the pharmacokinetics and tolerability of an intramuscular 15 mg meloxicam injection in comparison to the 15 mg oral tablet


Eligibility criteria:
inclusion criteria: * healthy subjects as determined by results of screening * written informed consent in accordance with good clinical practice and local legislation * age ≥ 18 and ≤ 50 years * broca \> - 20% and \< + 20% exclusion criteria: * any findings of the medical examination (including laboratory, blood pressure, pulse rate and electrocardiogram (ecg)) deviating from normal and of clinical relevance * gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders * surgery of the gastro-intestinal tract ( except appendectomy) * diseases of the central nervous system (such as epilepsy) or psychiatric disorders * chronic or relevant acute infections * hypersensitivity to meloxicam and/or non-steroidal antirheumatic agents * intake of drugs with a long half-life (\>24 hours) (≤ 1 month prior to administration or during the trial) * use of any drugs which might influence the results of the trial (≤ 10 days prior to administration or during the trial) * participation in another trial with an investigational drug (≤ 2 months prior to administration or during the trial) * smoker (\>= 10 cigarettes or \>= 3 cigars or \>= 3 pipes/day) * inability to refrain from smoking on study days * known alcohol abuse * known drug abuse * blood donation (≤ 1 month prior to administration) * excessive physical activities (≤ 5 days prior to administration) * history of hemorrhagic diatheses * history of gastro-intestinal ulcer, perforation or bleeding * history of bronchial asthma * for female subjects: * pregnancy * positive pregnancy test * no adequate contraception e.g. sterilization, iud (intrauterine device), oral contraceptives * inability to maintain this adequate contraception during the whole study period * lactation period
a study to measure the degree and effectiveness of the various vsculpt operating modes

Conditions: Sexual Dysfunction; Stress Incontinence

Summary: a pilot study to determine the degree and effectiveness of the various modes of vsculpt, an over-the-counter "otc" medical device, on enhanced genital blood flow and improvement in quality of life in menopausal women who suffer sexual dysfunction and stress incontinence

the primary aim of this study is to determine the degree and effectiveness of the various modes of vsculpt on enhanced genital blood flow with menopausal women who experience sexual dysfunction and stress incontinence as measured by temperature change in the genitalia immediately after initial and final treatment and an improvement in quality of life after using the vsculpt device over the course of four weeks. the secondary aim is to compare the differences in genital blood flow and improvement in quality of life of vsculpt's various modes against intone, another over-the-counter "otc" medical device that utilizes a different technology to treat stress incontinence and improve sexual dysfunction.

Eligibility criteria:
inclusion criteria: * study participants will be female * female participants who are capable of giving informed consent * female participants who are menopausal who have not had a menses within one year, and are within the ages of 48 and 60 * female participants who have had one or more vaginal births * female participants who are currently engaged in vaginal sexual intercourse with a partner * female participants who are presently experiencing bladder control issues either leakage, frequency or urgency * female participants who are presently experiencing pain during sexual intercourse exclusion criteria: * female participants shall not have an active sexually transmitted disease and/or infection * female participants who are actively undergoing chemotherapy * female participants who are currently taking any cancer-related drugs * female participants who are breastfeeding or lactating * female participants who have a medical history of neurological disorders (e.g., multiple sclerosis, parkinson's disease) * female participants with an active urinary tract infection (uti) * female participants with active bladder stones * female participants with active bladder tumor(s) * females with prior laser or vaginal rejuvenation surgeries or treatments * females with a medical history of vaginal cancer or radiation or surgery with exception of related to childbirth * females with prior non-invasive treatments (estrogen cream) or pelvic floor physical therapy for the vaginal area/ pelvic floor in the past six month * females with a physical disability precluding her from holding a lithotomy for an hour * females who are homeless
study of tremelimumab alone or combined with olaparib for patients with persistent eoc (epithelial ovarian, fallopian tube or primary peritoneal carcinoma)

Conditions: Primary Peritoneal Carcinoma

Summary: this study will be looking at what dose of tremelimumab and olaparib is safe and effective in patients with persistent eoc (epithelial ovarian, fallopian tube or primary peritoneal carcinoma).

this clinical trial was initially intended to be a phase 1/2 trial, but the trial never moved forward to phase 2 prior to termination.

Eligibility criteria:
inclusion criteria: 1. signed informed consent form 2. age ≥ 18 years 3. recurrent or persistent eoc (epithelial ovarian, fallopian tube or primary peritoneal carcinoma) 4. have archival tissue or willingness to undergo a tumor biopsy 5. have measurable disease 6. have had one prior taxane-platinum-based chemotherapeutic regimen 7. have had a treatment-free interval following platinum-based therapy of less than 12 months, have progressed during platinum-based therapy, or had persistent disease after a platinum-based regimen 8. have received hormonal therapy 9. ecog performance status of 0 to 1 10. ability to take oral medications 11. hiv, htlv-1, hbv, and hcv negative 12. adequate organ and bone marrow function as defined by study-specified laboratory tests 13. normal blood coagulation parameters 14. life expectancy greater than 16 weeks 15. must use acceptable form of birth control through the study and for 28 days after final dose of study drug 16. willing and able to comply with study procedures exclusion criteria: 1. prior therapy with an anti-ctla-4 antibody or parp inhibitor 2. active infection requiring antibiotics 3. active autoimmune disease 4. active and uncontrolled intercurrent illness 5. history of other cancers within the past 5 years 6. systemically active steroid use 7. receiving systemic chemotherapy or radiotherapy within 4 weeks prior to the first dose of study drug 8. use of ketoconazole, itraconazole, ritonavir, indinavir, saquinavir, telithromycin, clarithromycin and nelfinavir 9. requirement for chronic parenteral hydration/nutrition 10. vaccination with live attenuated vaccine within 1 month prior to first dose of study drug 11. patients with untreated brain metastases, treated brain metastases that are not stable, leptomeningeal disease, or seizures uncontrolled with standard medical therapy 12. patients with myelodysplastic syndrome/acute myeloid leukaemia 13. history of diverticulitis 14. history of bleeding disorder or diathesis. 15. serious or nonhealing wound, ulcer, bone fracture, or osteonecrosis of the jaw 16. major surgical procedure within 28 days of study enrollment, or anticipated while on study. 17. pregnant or breast feeding woman

Keywords: fallopian tube epithelial ovarian eoc
a study to test the effect of cdp870 in the treatment of crohn's disease over 26 weeks, comparing cdp870 to a dummy drug (placebo)

Conditions: Crohn's Disease

Summary: a 26 week study to examine the efficacy, safety and pharmacokinetics of cdp870 in crohn's disease

receiving immunosuppressants (azathioprine/6-mp/methotrexate) at week 0 or not. 604 patients will be enrolled with 1006 patients screened (to allow for 25% screen failures between screening and week 0 and expected presentation at screening of 60% of patients with crp \< 10 mg/l and 40% of patients with crp ≥ 10 mg/l).

Eligibility criteria:
inclusion criteria: * definitive diagnosis of crohn's disease confirmed (at least 3 months prior to study entry) either by radiological, endoscopic or histological evidence, affecting the terminal ileum (l1), colon (l2) or ileocolon (l3\*. \*vienna classification (1998) * active crohn's disease (≥ 220 and ≤ 450) scored over the 7 days prior to the first dose of study drug. * male and female aged 18 years or above at screening. * patients who meet all concomitant medication criteria in the protocol specified table. for all drugs being taken at screening, the patient should be able to remain on a stable dose throughout the duration of the study, although steroids may be tapered starting at weeks 8 to 12. exclusion criteria: * crohn's disease related * fistula abscess present at screening. * stricturing type disease with symptoms or signs of non-inflammatory mechanical obstruction or bowel perforation in last 3 months. * short bowel syndrome. * functional colostomy or ileostomy (note: patients who have had a temporary stoma in the past, which has been reversed, are eligible to enter the study). * positive stool laboratory results for enteric pathogens.

Keywords: crohn's disease, cdp870, cdai, clinical response, remission, certolizumab pegol, cimzia
correlation of venous oxygen saturation measurements by non-invasive mespere venous oximeter and central venous catheter

Conditions: Validation of Oximeter System

Summary: the purpose of this study is to establish the accuracy of the non-invasive mespere oximeter that estimates venous oxygen saturation.

the conventional pulse oximeter has been a standard in clinical care for non-invasive hemodynamic monitoring, which only measures arterial blood oxygenation. the clinical application of venous oximetry is numerous, including severe sepsis and septic shock, severe trauma and hemorrhagic shock, and heart failure and cardiac arrest. the existing method for venous blood oxygenation monitored is either through an invasive fiber optic catheter, or intermittently by blood sampling and co-oximetry. however, catheterization can be costly and can include inherent risks. therefore, due to the inherent risks of catheterization, venous oximetry is limited only to critically ill patients. by non-invasively monitoring venous blood oxygenation, the mespere oximeter provides more complete information on patient hemodynamics.

Eligibility criteria:
inclusion criteria: * age 18 and older * heart failure patients already receiving rhc as part of their usual care * signed written and informed consent exclusion criteria: * lack of patient consent * subject is pregnant * evidence of abnormal neck anatomy * subject does not have visible left and right jugular veins * subject has occluded internal jugular veins under ultrasound imaging * allergic to adhesive tape * ongoing photodynamic therapy * presence of known anatomical shunt or av dialysis fistula * known central vein stenosis

Keywords: venous oximeter non-invasive monitor heart failure (hf)
internet-delivered cognitive behavioural therapy for adolescents with anxiety

Conditions: Anxiety

Summary: the purpose of this study is to evaluate the effects of learning support and chat on treatment outcome in internet-administrated cognitive behaviour therapy (icbt) for adolescents with anxiety.

the study is set up as a factorial design with two independent variables: 1: learning support and 2: chat-sessions in real time. the intervention tested is based on cognitive behavior therapy delivered over the internet via a secure treatment platform. participants in the study are recruited from the general public via social media. the intervention is in swedish.

Eligibility criteria:
inclusion criteria: * be between the ages of 15-19 years old * have symptoms of anxiety, anxiety disorder exclusion criteria: * suicidal ideation * alcohol addiction * other major primary psychiatric disorder * ongoing psychological treatment * recent (during last 4 weeks) change in psychiatric medication

Keywords: learning support chat adolescents
ventilation efficacy of size 3 or size 4 i-gel in female patient weighing 50 to 60 kilograms

Conditions: Body Weight; Breast Neoplasms; Laryngeal Masks

Summary: currently, the main method for selecting an i-gel® size is based on the body weight recommendation (30-60 kg for size 3 and 50-90 kg for size 4) according to the manufacturer's recommendation. however, there is an overlapping in size selection in people weighing between 50 and 60 kilograms. laryngeal mask airways are widely used for breast surgery, and this patient cohort is often weighed between 50-60 kilograms in national taiwan university hospital. therefore, in this randomized clinical trial, the investigators will compare the ventilation efficacy of size 3 and size 4 i-gel® in anesthetized, paralyzed female patients weighing 50 to 60 kilograms who undergo breast surgery. also, the investigators will record any side effects of size 3 and size 4 i-gel® in this cohort.

with the introduction of the laryngeal mask, it has been widely used for the management of airway during general anesthesia. compared to the endotracheal tube, it has the advantages of easier and faster placing, reducing the proportion of a sore throat and other benefits. the i-gel® is a second-generation of the laryngeal mask. compared to the classic laryngeal mask, it provides higher sealing pressure and better airway protection to reduce respiratory complications. choosing an appropriate size laryngeal mask is an important issue. trauma during placing or positive ventilation failure may occur if the wrong size is selected. currently, the main method for selecting an i-gel® size is based on the body weight recommendation (30-60 kg for size 3 and 50-90 kg for size 4) according to the manufacturer's recommendation. however, there is an overlapping in size selection in people weighing between 50 and 60 kilograms. laryngeal mask airways are widely used for breast surgery, and this patient cohort is often weighed between 50-60 kilograms in national taiwan university hospital. therefore, in this randomized clinical trial, the investigators will compare the ventilation efficacy of size 3 and size 4 i-gel® in anesthetized, paralyzed female patients weighing 50 to 60 kilograms who undergo breast surgery. also, the investigators will record any side effects of size 3 and size 4 i-gel® in this cohort. keywords: airway management; laryngeal mask airway; breast surgery

Eligibility criteria:
inclusion criteria: * age \> 20 years old. * asa physical status i and ii. * elective breast surgery. * female with a body weight of 50 - 60 kilograms. exclusion criteria: * high risk of aspiration. (defined as history of gastroesophageal reflux, hiatal hernia, previous gastric surgery, and those who take medications for disorders of gastrointestinal motility) * previous head \& neck surgery. * previous head \& neck concurrent chemoradiotherapy (ccrt) * reactive airway disease: chronic obstructive pulmonary disease (copd), asthma, upper respiratory infection in recent two weeks * exposure to tobacco * pregnancy

Keywords: laryngeal mask airway breast surgery
comparison between moderate-high interval exercise and moderate continuous exercise in an advanced cardiac rehabilitation program

Conditions: Coronary Artery Disease; Myocardial Infarction

Summary: the research will study the differences between interval training and continuous training among cardiac patients in a cardiac rehabilitation facility. the main objectives are: 1. functional capacity measures (vo2 max). 2. cardiac risk factors 3. quality of life assessments. study hypothesis: interval training will be more effective in improving functional capacity, cardiac risk factors and quality of life, compared to continuous training.


Eligibility criteria:
inclusion criteria: * patients undergone: * myocardial infarction * percutaneous transluminal coronary angioplasty * coronary artery bypass graft exclusion criteria: * patients with: * severe ischemia or angina * implantable cardioverter-defibrillator * pacemakers transplants * severe left ventricular dysfunctions * uncontrolled arrhythmias
study of gsk3845097 in previously treated participants with advanced synovial sarcoma and myxoid/round cell liposarcoma

Conditions: Neoplasms

Summary: to assess the safety, tolerability and determine recommended phase 2 dose (rp2d) of gsk3845097 in hla-a\*02:01, hla-a\*02:05 and/or hla-a\*02:06 positive participants with new york esophageal squamous cell carcinoma (ny-eso)-1 and/or cancer testis antigen 2 (lage-1a) positive, previously treated, advanced (metastatic or unresectable) synovial sarcoma (ss) and myxoid/round cell liposarcoma (mrcls).

this study is a substudy of the master record - (209012) nct04526509.

Eligibility criteria:
inclusion criteria: * participant must be \>=18 years of age and weighs ≥40 kg on the day of signing informed consent * participant must be positive for hla-a\*02:01, hla-a\*02:05, and/or hla-a\*02:06 alleles * participant's tumor must have tested positive for ny-eso-1 and/or lage-1a expression by a gsk designated laboratory * performance status: eastern cooperative oncology group of 0-1 * participant must have adequate organ function and blood cell counts 7 days prior to leukapheresis * participant must have measurable disease according to recist v1.1. * participant has advanced (metastatic or unresectable) ss or mrcls confirmed by local histopathology with evidence of disease-specific translocation * participant has completed at least one standard of care (soc) treatment including anthracycline containing regimen unless intolerant to or ineligible to receive the therapy. * participants who are not candidates to receive anthracycline should have received ifosfamide unless also intolerant to or ineligible to receive ifosfamide. participants who received neoadjuvant/adjuvant anthracycline or ifosfamide based therapy and progressed will be eligible exclusion criteria: * central nervous system (cns) metastases, with certain exceptions for cns metastases in nsclc as specified in the protocol * any other prior malignancy that is not in complete remission * clinically significant systemic illness * prior or active demyelinating disease * history of chronic or recurrent (within the last year prior to leukapheresis) severe autoimmune or immune mediated disease requiring steroids or other immunosuppressive treatments * previous treatment with genetically engineered ny-eso-1-specific t cells, ny-eso-1 vaccine or ny-eso-1 targeting antibody * prior gene therapy using an integrating vector * previous allogeneic hematopoietic stem cell transplant within the last 5 years or solid organ transplant * washout periods for prior radiotherapy and systemic chemotherapy must be followed * major surgery within 4 weeks prior to lymphodepletion * pregnant or breastfeeding females

Keywords: adoptive t-cell therapy advanced synovial sarcoma advanced myxoid/round cell liposarcoma advanced tumors gsk3845097 t cell receptor leukapheresis